gantenerumab monoclonal antibody treatment alzheimers disease developed hoffmannla roche gantenerumab binds clears aggregated beta amyloid phase iii clinical trial gantenerumab stopped early lack gantenerumab also evaluated younger patients high risk developing alzheimers five years treatment drug little slow cognitive decline monoclonal article stub help wikipedia expanding drug article relating nervous system stub help wikipedia expanding httpsenwikipediaorgwikigantenerumab